For the majority of patients with pancreas cancer, the high metastatic proclivity is life limiting. Some patients, however, present with and succumb to locally destructive disease. A molecular understanding of these distinct disease manifestations can critically inform patient management. Using genetically engineered mouse models, we show that heterozygous mutation of Dpc4/Smad4 attenuates the metastatic potential of Kras G12D/+ ;Trp53 R172H/+ pancreatic ductal adenocarcinomas while increasing their proliferation. Subsequent loss of heterozygosity of Dpc4 restores metastatic competency while further unleashing proliferation, creating a highly lethal combination. Expression levels of Runx3 respond to and combine with Dpc4 status to coordinately regulate the balance between cancer cell division and dissemination. Thus, Runx3 serves as both a tumor suppressor and promoter in slowing proliferation while orchestrating a metastatic program to stimulate cell migration, invasion, and secretion of proteins that favor distant colonization. These findings suggest a model to anticipate likely disease behaviors in patients and tailor treatment strategies accordingly.
SUMMARY
For the majority of patients with pancreas cancer, the high metastatic proclivity is life limiting. Some patients, however, present with and succumb to locally destructive disease. A molecular understanding of these distinct disease manifestations can critically inform patient management. Using genetically engineered mouse models, we show that heterozygous mutation of Dpc4/Smad4 attenuates the metastatic potential of Kras G12D/+ ;Trp53 R172H/+ pancreatic ductal adenocarcinomas while increasing their proliferation. Subsequent loss of heterozygosity of Dpc4 restores metastatic competency while further unleashing proliferation, creating a highly lethal combination. Expression levels of Runx3 respond to and combine with Dpc4 status to coordinately regulate the balance between cancer cell division and dissemination. Thus, Runx3 serves as both a tumor suppressor and promoter in slowing proliferation while orchestrating a metastatic program to stimulate cell migration, invasion, and secretion of proteins that favor distant colonization. These findings suggest a model to anticipate likely disease behaviors in patients and tailor treatment strategies accordingly.
INTRODUCTION
Patients with carcinomas die primarily of metastatic disease. This is especially true of pancreatic ductal adenocarcinoma (PDA), which is notorious for its early and extreme penchant for dissemination. A minority of patients instead presents with and succumbs to locally advanced disease, although the reasons for these distinct presentations remain unknown. PDA has either overtly metastasized or advanced locally beyond the boundaries of surgical resection in most patients at the time of diagnosis; subsequent median survival is approximately 4.5 and 10.6 months, respectively (Hidalgo, 2010) . For the fortunate few for whom surgical resection is possible, median survival increases to 2 years but is not durable: survival at 5 years is only 20% and declines to less than 2% at 10 years (Allison et al., 1998) . The majority of these post-operative patients also eventually die of metastatic disease suggesting that clinical stage I tumors are, in fact, already micrometastatic stage IV.
In a uniformly lethal disease, prognosis per se may be less informative than the ability to predict disease behaviors and likely proximal cause of death to help inform rational treatment decisions. Indeed, neoadjuvant strategies for early-stage PDA were introduced because many patients ultimately die from distant relapse after surgery; addressing this reality with a course of chemotherapy prior to resection can prolong survival but runs the attendant risk of local tumor growth beyond surgical boundaries and therefore a lost chance for cure. Thus, knowing when to operate or irradiate and when to treat systemically remains unclear.
PDA begins most commonly in precursor lesions termed pancreatic intraepithelial neoplasms (PanIN) that arise in terminal ductules (Hruban et al., 2001) . Activating KRAS mutations occur early in preinvasive disease and are almost uniformly present (>90%) in invasive PDA. Mutations in CDKN2A/INK4A are similarly abundant in invasive disease (>95%) and point mutations in TP53 are also common (>75%). Loss of DPC4/SMAD4 expression, the last of the principal genetic events associated with PDA, occurs late in PanIN-to-PDA progression and is seen in approximately 50% of invasive cancers (IacobuzioDonahue et al., 2000) .
Engineering these cardinal mutations into the murine pancreas has yielded important insights into mechanisms underlying initiation, progression, and maintenance of PDA, as well as the non-cell autonomous contributors to disease biology (Pé rezMancera et al., 2012; Stromnes et al., 2014) . Collectively, these studies suggest that distinct combinations of tumor suppressor gene mutations can alter the pace, phenotype, and prognosis of the resultant invasive disease. For example, concomitant mutations in p16/p19 (Aguirre et al., 2003) or Trp53 (Hingorani et al., 2005) hasten progression initiated by oncogenic Kras (Hingorani et al., 2003) , albeit with distinct characteristics. In the case of biallelic p16/p19 loss, the primary tumor progresses rapidly, leading to early death and minimal metastatic disease. Kras ;Trp53
LSL-R172H/+
;Cre (KPC) animals instead succumb from a combination of both primary and metastatic tumor burdens that closely mimics the common presentation in humans. In contrast, heterozygous deletion of Dpc4/Smad4 (Izeradjene et al., 2007) . Subsequent progression to invasive PDA occurs through additional spontaneous events including loss of heterozygosity (LOH) of Dpc4, but the disease manifests an attenuated metastatic potential. Invasive PDA that arise from MCN in patients also invariably lose DPC4 expression and have a better prognosis than cancers following the more common PanIN-to-PDA route (Crippa et al., 2008) . Thus, perhaps unexpectedly, decreased transforming growth factor b (TGF-b) signaling in certain contexts can give rise to less aggressive PDA.
Continuing these investigations into the pathophysiology of distinct genetic and histologic subtypes of PDA, we engineered targeted heterozygous mutation of Dpc4 with concomitant point mutant Trp53
R172H and oncogenic Kras G12D in the murine pancreas and defined the resulting disease. We describe a biphasic dependency of Runx3 levels on Dpc4 gene dosage that helps to predict and explain three potential disease presentations in patients. The predicted behaviors can, in turn, inform the rational application and timing of local versus systemic therapies to maximize survival.
RESULTS

Concomitant Trp53
Mutation Restores PanIN-to-PDA Progression in the Context of Kras G12D Expression and Dpc4 Deletion Conditional endogenous expression and deletion of critical genes ( Figure S1A ) were targeted to the developing murine pancreas using strategies described previously (Hingorani et al., 2003 (Hingorani et al., , 2005 Izeradjene et al., 2007) . We first established that animals with targeted pancreatic expression of point mutant p53 and concomitant heterozygous deletion of Dpc4/ Smad4, in the absence of oncogenic Kras G12D , developed and aged normally with unperturbed pancreatic parenchymal architecture and intact exocrine and endocrine synthetic functions ( Figure S1B ). Figure 1A ). KPDC animals developed solid, multinodular tumors similar to those of KPC mice ( Figures 1B and 1C ), albeit much larger ( Figures 1D and 1E ). Histologic progression in KPDC mice followed the classical PanIN-to-PDA and not MCN-to-PDA sequence. Low-grade PanIN were seen in young animals and subsequently progressed to higher grade and then to invasive PDA ( Figures 1F-1I ). CK-19 expression ( Figure 1J) confirmed the ductal epithelial nature of these neoplasms, and Alcian blue revealed their abundant cytoplasmic mucin (Figure 1K ). The histologic morphology was predominantly glandular (Table S1 ) and other less common histologies seen in human PDA, including anaplastic and sarcomatoid, were similarly rare in KPDC tumors.
Haploinsufficiency of Dpc4
Attenuates the Metastatic Drive of Kras G12D and Trp53
R172H
Belying their earlier demise, KPDC animals manifested an unexpected and significant decrease in metastatic disease. Their KPC littermates developed widely disseminated disease as described previously (Hingorani et al., 2005) , with a heavy macroscopic tumor burden, principally to the liver (53%) and lungs (47%) ( Figure 1L ). In contrast, only 21% of KPDC littermates developed macroscopically evident metastases, which were largely confined to the liver ( Figure 1L ; Table S1 ). Moreover, as most metastases in KPDC mice were microscopic, they did not contribute substantively to overall tumor burden. Thus, the evolution of pancreas cancer in KPDC mice is shifted toward a higher primary tumor burden and less metastatic disease.
Genetic Progression of KPDC PDA To investigate the basis for the distinct in vivo biological behavior of KPDC PDA, we purified primary ductal carcinoma cells as previously described (Hingorani et al., 2005; Schreiber et al., 2004) . We first confirmed that the purified PDA cells had recombined and activated the conditional Kras LSL-G12D and
Trp53
LSL-R172H alleles, and likewise deleted the Dpc4 allele (Figures S1C-S1E). Disease progression was invariably accompanied by spontaneous LOH of Trp53 ( Figure S1D ), as typically occurs in murine (Hingorani et al., 2005) and human (Scarpa et al., 1993) PDA with point mutations in one TP53 allele. Invasive KPDC PDA cells typically did not undergo LOH of Dpc4 but instead frequently retained the remaining wild-type (WT) allele ( Figure S1E ) and persistent protein expression ( Figure 1M ), unlike the spontaneous loss or epigenetic silencing of the second allele that occurs in KDC mice during disease progression (Izeradjene et al., 2007) . Detectable levels of Trp53 were observed consistent with point mutant expression and LOH. Cdkn2a/ Ink4a (p16) expression was frequently lost, although that of the contiguous p19 allele was retained, suggesting specific promoter methylation rather than genomic deletion as the mechanism of silencing (Izeradjene et al., 2007) . The loss of p16 is notable as prior studies of both KPC (Hingorani et al., 2005) and Kras LSL-G12D/+ ;p16/p19 À/À ;Cre (Bardeesy et al., 2006) animals found no additional loss of other major tumor suppressor genes (TSG) during disease progression, establishing non-overlapping mutational spectra in the two model systems. Thus, heterozygous mutation of Dpc4 increases the selection pressure to lose p16, underscoring that WT levels of Dpc4 can be tumor promoting in this context and that the haploinsufficiency of Figures  S2E-S2G ). After injection into the circulation, KPC cells formed numerous large pleural and parenchymal metastases sufficient to induce respiratory failure, reflecting the metastatic aggressiveness seen in their autochthonous counterpart (Figures 2G and 2H) . KPDC cells formed far fewer and smaller lung metastases in animals that remained clinically robust at comparable time points (Figures 2F and 2H) . Collectively, these studies reveal that both the baseline properties and responses to TGF-b are essentially mirror images in the presence of WT versus heterozygous loss of Dpc4.
Runx3 Drives Metastasis in PDA
The dramatically different behaviors of KPC and KPDC carcinomas suggested that comparative expression profiling might provide mechanistic insights. Expression analyses using customized TGF-b-signaling-specific quantitative PCR (qPCR) arrays identified 15 genes that were upregulated at least 2-fold in KPC versus KPDC cells and that might therefore represent metastasis-promoting genes (Table S2 ). Dpc4 expression was approximately 2-fold higher in KPC than KPDC cells, confirming the fidelity of the array results. Completely distinguishing itself was Runx3, which was upregulated 36-fold in KPC cells (Table  S2) . Runx3 belongs to a family of runt-related transcription factors involved in development and differentiation of which Runx1 and Runx2 are the best characterized (Blyth et al., 2005) . The specificity of Runx3 upregulation was underscored by the lack of significant changes in the other family members (1.2-fold increase for Runx1 and 1.5-fold for Runx2; data not shown). RUNX1 and RUNX2 have been identified as TSG in hematopoietic malignancies. Its alternate designation as acute myelogenous leukemia 2 (AML2) notwithstanding, what little is known about the role of RUNX3 in malignancy comes primarily from studies of solid tumors, where it has been implicated on both sides of the cancer divide (i.e., as a TSG in some reports and an oncogene in others). Indeed, its specific role in tumorigenesis remains the subject of considerable controversy (for examples, see Ito et al., 2009; Levanon et al., 2001 Levanon et al., , 2011 Li et al., 2002; see below) .
Runx3 gene expression and protein levels correlated with metastatic potential ( Figures 3A and 3B ). In both KPC and KPDC carcinoma cells, Runx3 was appropriately localized to the nuclear compartment ( Figure S3A ), albeit at very different levels. Specific immunohistochemistry (IHC) for Runx3 revealed no discernible expression in normal pancreatic ducts, islets, or acini; scattered lymphocytes, common sites of elevated Runx3 and useful internal controls (Yarmus et al., 2006) , showed strong nuclear expression ( Figure 3C ). As expected, KPC tumors had moderate-to-strong nuclear Runx3 expression (Figures 3D and 3E) , whereas KPDC tumors typically showed very weak expression (Figures 3F and 3G) . Preinvasive lesions adjacent to invasive KPC carcinomas also lacked Runx3 expression ( Figure 3H ). KPC metastases exhibited strong nuclear Runx3 expression (Figure 3I) and, in KPDC mice that did bear metastases, both these and the primary tumors often expressed high levels of Runx3 ( Figures 3J-3L ). The upregulation of Runx3 as KPC PanIN become invasive and metastatic coincides with the apparent requirement for LOH of p53 and subsequent accumulation of the point mutant protein (Hingorani et al., 2005) . These observations implicate WT p53-reported to complex with RUNX3 (Yamada et al., 2010) -in suppressing Runx3 or point mutant p53 in stabilizing Runx3.
Runx3 Promotes Metastatic Seeding and Colonization by Remodeling the Extracellular Matrix
To further investigate its effects on metastatic potential, we varied Runx3 expression in independent KPDC and KPC carcinoma cell lines (Figures S3B and S3C) . Runx3 overexpression greatly increased the basal migration of KPDC cells, and silencing Runx3 inhibited KPC cell migration ( Figures 3M, S3D , and S3E). TGF-b stimulated migration only in the context of high Runx3 expression. Anchorage-independent growth in soft agar was similarly influenced by changes in Runx3 expression (data not shown). KPDC$Runx3 cells also readily formed lung metastases in immunocompromised mice ( Figures 3N and 3O ), an ability virtually absent in control-transfected KPDC cells and once again more like baseline KPC cells. A trend toward reduced lung metastasis after Runx3 knockdown in KPC cells was also observed but did not reach statistical significance, perhaps reflecting incomplete Runx3 silencing (Figures 3P and 3Q) .
KPDC cells were unable to efficiently seed metastases even after direct inoculation into the bloodstream. To successfully colonize a distant site, disseminated cells must not only intravasate but also survive in the circulation, extravasate in a target organ, and fashion a niche that supports metastatic growth. We therefore performed focused array profiling for extracellular matrix (ECM) genes comparing the highly metastatic KPC and non-metastatic KPDC PDA cells. A survey of the top differentially (legend continued on next page)
expressed genes revealed several that have been previously implicated in critical ECM functions, promoting local invasiveness and remodeling of the metastatic niche (Psaila and Lyden, 2009) (Table S3) . These include Mmps, Timps, Versican, Spp1, and Sparc (Lunardi et al., 2014) . Osteopontin (SPP1) is upregulated in human PDA and portends poor prognosis (Poruk et al., 2013) . Spp1 protein ( Figure 4A ) and transcript levels (Table S3) are also significantly upregulated in KPC versus KPDC PDA cells. We identified two consensus RUNX3-binding sites and two SMAD-binding elements in both the human SPP1 and murine Spp1 promoter regions and found that the promoter responds to RUNX3 overexpression ( Figure S4A ). Overexpression or silencing of Runx3 in KPDC or KPC cells, respectively, caused corresponding changes in Spp1 expression ( Figures 4B, 4C , S4B, and S4C). As Spp1 is secreted, we therefore tested whether exogenously added Spp1 influenced migration. KPDC cell migration increased significantly in the presence of Spp1, an effect reversed by a neutralizing Spp1 antibody, which also significantly reduced basal KPC cell migration ( Figure 4D ). Spp1 promotes migration through binding to integrins and CD44 receptors, which are also upregulated in KPC cells (Table S3) , and we found that anti-CD44 antibody decreased Spp1-mediated migration compared to immunoglobulin G (IgG) controltreated counterparts ( Figure 4D ). Finally, if Spp1 secretion is important for distant colonization, then circulating plasma levels should be high in mice with metastases regardless of genotype. Circulating Spp1 was indeed elevated in the majority of KPC mice, and the relatively few KPDC mice, that developed significant metastatic disease burdens ( Figure 4E ).
Some genes in the ECM profile, including the top-ranked one, Col6a1, were less familiar (Table S3 ). COL6A1 binds fibrillar type I collagen (Bonaldo et al., 1990) , itself complicit in PDA aggressiveness and dissemination (e.g., Armstrong et al., 2004) . COL6A1 is elevated in the circulating proteome of PDA patients (Yu et al., 2009 ), and we found two RUNX3 consensus-binding sites in the COL6A1/Col6a1 promoter region (data not shown). Little is known, however, about the specific function(s) of this gene in cancer and, in particular, in PDA. We first confirmed that Col6a1 is differentially expressed in KPC and KPDC cells ( Figures 4F and S4D) . Overexpression of Runx3 in KPDC cells increased Col6a1 transcript and protein levels ( Figures 4G and  S4D ), whereas Runx3 silencing in KPC cells reduced them (Figures 4H and S4E) . We next tested whether Col6a1 could act as an autocrine enabler of dissemination. KPC cells secrete higher levels of Col6a1 than KPDC cells ( Figure 4I ), and overexpressing Col6a1 in KPDC cells increased migration and silencing Col6a1 in KPC cells inhibited it ( Figures 4J and S4F-S4I ). Thus, in addition to providing a potentially critical component of the threedimensional architecture of a developing tumor, Col6a1 also appears to directly stimulate cell motility. Finally, overexpression of Col6a1 in KPDC or knockdown in KPC cells reversed their respective abilities to seed lung metastases after intravenous injection ( Figures 4K and 4L) . Overall, these results suggest that Runx3 serves to both expel the seed and prepare the soil by directly stimulating cell migration and dissemination, and by inducing the expression of a repertoire of proteins that can reengineer the extracellular matrix to enhance distant colonization.
Heterozygous Deletion of
Dpc4 Increases Proliferation in the Context of Oncogenic Kras G12D and Trp53
R172H
The increased primary tumor size at the expense of metastatic disease seen in KPDC compared with KPC PDA could be explained by increased proliferation, decreased apoptosis, or both. Ki-67 expression was significantly increased in KPDC versus KPC autochthonous tumors and apoptosis was similarly negligible in both contexts ( Figures 5A-5E ). In culture, KPDC PDA cells were more proliferative than KPC cells ( Figure 5F ) and had similarly low apoptotic rates (data not shown). KPDC cells were also somewhat less sensitive to growth arrest by TGF-b ( Figure 5F ). Substantiating its sometime designation as a TSG, silencing Runx3 in KPC cells unleashed proliferation and overexpression of Runx3 in KPDC cells inhibited it ( Figures  5G and 5H ). We identified multiple consensus Runx3 binding sites in the p21 Cip1/Waf1 (Cdnk1a) promoter region and confirmed that Runx3 stimulated its expression ( Figure 5I ), as previously demonstrated in gastric epithelial cells (Chi et al., 2005) .
Rare Metastasis of KPDC PDA Requires LOH of Dpc4
The above findings prompted an analysis of Dpc4 status in paired primary tumors and metastases in the few KPDC animals that did develop disseminated disease. The primary tumors revealed focal areas of Dpc4 loss, suggesting a potential source for the disseminated cells ( Figures 6A and 6B ). In addition, a strong inverse correlation was observed between Dpc4 and Runx3 expression in primary tumors and metastases ( Figures  6C and 6D ): complete loss of Dpc4 was associated with elevated levels of Runx3, whereas retained Dpc4 corresponded with low-to-undetectable Runx3 ( Figure S5A ). These observations suggested that completing the loss of Dpc4 in PDA cells that had undergone a first (heterozygous) ''hit'' may confer metastatic potential on cells that previously lacked it, perhaps by increasing Runx3.
To directly investigate the effects of homozygous loss of Dpc4 on autochthonous PDA, we generated and characterized (L) Quantification of metastatic pulmonary tumor burden from assays in (K). Two different histological levels from a total of three injected animals were assessed (mean ± SEM; *p < 0.05). See also Figure S4. (data not shown). Large, multinodular pancreas tumors were found to develop from PanIN precursors (Figures S5B and S5C) and were histologically indistinguishable from KPDC or KPC PDA (Figures S5D and S5E) . KPDDC primary tumors grew much faster than KPDC and KPC PDA, as may be expected from complete loss of canonical TGF-b signaling ( Figure S5F ). In addition, KPDDC mice exhibited metastases to the liver and lungs at similar frequencies (73%) to KPC mice, a capability reflected in the elevated levels of Runx3 in KPDDC primary tumors ( Figure S5G ) and purified cells ( Figure S5H ). This combination of unfettered proliferation and potent dissemination explains the rapid demise of KPDDC mice and is consistent with the subset of especially aggressive human PDA with a similar mutational profile (Yachida et al., 2012) . In keeping with the role of Runx3 in modulating ECM gene expression to promote metastasis, Spp1 and Col6a1 were also elevated in KPDDC compared to KPDC cells ( Figure S5H ). Despite their considerable metastatic competency in vivo, KPDDC cells were nevertheless notably resistant to induction of EMT by TGF-b in vitro ( Figures 6E, S5I , and S5J). Collectively, these findings suggest a biphasic dependency of metastatic potential on Dpc4-mirrored in Runx3 levels-with heterozygous mutation retarding, and subsequent LOH rescuing, the ability to disseminate ( Figure 6F ).
Multiple Inputs Regulate Runx3 Levels
In considering how Runx3 levels might be regulated, three pieces of information provided useful starting points: (1) the dramatic fall and rise in Runx3 levels with stepwise loss of Dpc4; (2) the increase in Runx3 levels coordinately with LOH of p53 in KPC PDA progression; and (3) the presence of multiple consensus binding sites for the Runx3 transcription factor in its own promoter. Although the detailed mechanisms behind the complex regulation of Runx3 levels remain to be elucidated, a working model can nevertheless be elaborated from our findings and corroborated experimentally ( Figure 6G ). First, we hypothesized that WT p53 promotes Runx3 protein degradation and that point mutant p53 rescues this effect. This predicts therefore that protein stability would be highest in invasive KPC cells and that Runx3 stability should otherwise be comparable in KPDC and KPDDC cells (as both undergo LOH of p53), unless Dpc4 status additionally contributes. We incubated cells in cycloheximide to arrest protein synthesis and followed the kinetics of Runx3 degradation: protein levels were indeed most stable in KPC cells, and the already low Runx3 levels in KPDC cells dropped even further ( Figures S5K and S5L ). These findings suggested that homozygous levels of Dpc4 promoted Runx3 synthesis (which would most readily be accomplished at the transcriptional level) and that heterozygous levels were sufficient to promote Runx3 protein degradation. We predicted therefore that restoring Dpc4 expression in KPDC cells would increase Runx3 transcript levels and that partial knockdown in KPC would decrease them, both of which were observed ( Figures S5M and S5N ). That the basal protein levels are both elevated and more stable in KPDDC than KPDC cells is also consistent with this interpretation, but suggests the presence of at least one more input into Runx3 transcription, perhaps Runx3 itself. In this scenario, once the concentration of the Runx3 transcription factor achieves a critical threshold, it further promotes its own transcription. The Runx3 promoter contains three consensus Runx3 binding sites, prompting us to test this hypothesis directly in reporter assays with increasing amounts of exogenous Runx3 ( Figure S5O ). As shown, once Runx3 rises above a certain level, it rapidly increases its own transcription.
RUNX3 Drives Metastasis in Human PDA
To determine whether RUNX3 served similar roles in human pancreas cancer, we first assessed protein levels in a panel of well-characterized human PDA cell lines ( Figure 7A ). There are wide differences across these extensively passaged cell lines in the mutational status of the principal TSG, and even among multiple reports of a single line (Deer et al., 2010) . Moreover, as disease behavior may also reflect the chronologic sequence in which mutations arise (see Izeradjene et al., 2007) and we cannot know that history, we asked whether RUNX3 levels alone could be used to infer metastatic capability. We chose two of the highest (CFPAC-1 and Panc-1) and one of the lowest (MiaPaCa-2) RUNX3-expressing lines for further study ( Figure 7A ). We note that, although MiaPaCa-2 cells are WT for DPC4, they contain markedly decreased-but not completely absent-levels of TGF-bR2 (data not shown), suggesting an alternative way to attenuate DPC4-mediated signaling and potentially produce the same functional outcome. Basal levels of RUNX3 predicted migration, as MiaPaCa-2 cells migrated less well than either CFPAC-1 or Panc-1 cells (Figures 7B and 7C) . The respective responses of these cell lines to TGF-b also followed the pattern seen with murine PDA cells: TGF-b modestly inhibited MiaPaCa-2 cell migration, as it did with KPDC cells, whereas it promoted (or left unaffected) the high basal migration of CFPAC-1 and Panc-1 cells, similar to KPC cells. Overexpression of RUNX3 in MiaPaCa-2 cells (Figure S6A ) greatly increased migration ( Figures 7B and S6B) . Conversely, depletion of RUNX3 in both Panc-1 cells and CFPAC-1 cells inhibited migration ( Figures 7C, S6C, and S6D) . Anchorage-independent growth of MiaPaCa-2 and CFPAC-1 cells was similarly influenced by RUNX3 overexpression and knockdown, respectively ( Figures S6E and S6F ). MiaPaCa-2 cells overexpressing RUNX3 developed a significantly greater metastatic burden after intravenous inoculation into NOD.SCID mice than vector-control cells (Figures 7D and 7E) . Conversely, targeted depletion of RUNX3 in Panc-1 cells diminished their overall metastatic potential. Although both control and RUNX3-knockdown Panc-1 cells produced a comparable metastatic burden in the lungs (Figure S6G ), the ability to seed and support secondary liver metastases was significantly impaired by RUNX3 depletion as reflected in the distinct gross pathology ( Figure 7F ) and liver weights between the two groups: 4.3 ± 0.6 g (n = 4) versus 0.53 ± 0.06 g (n = 3; p < 0.005), respectively. SPP1 and COL6A1 expression levels were also influenced as expected by modulating RUNX3 expression in these respective human cell lines, and COL6A1 overexpression stimulated migration ( Figures S6H-S6K) . Thus, the RUNX3-dependent metastatic drive and responses to TGF-b observed in human PDA cells paralleled the behaviors of their murine counterparts.
RUNX3 Predicts Survival and Disease Behavior in Human PDA
Cohorts of PDA patients with evaluable tissue and long-term survival data are rare. Using the available resources, we investigated whether RUNX3 levels in primary tumors influenced disease behavior and survival after surgery and could even predict response to various forms of therapy. Given the predilection for distant relapse after surgery, we hypothesized that high RUNX3 levels in primary PDA epithelial cells might portend poor prognosis. In a cohort of PDA patients who underwent definitive resection (n = 88), RUNX3 levels did indeed correlate with survival ( Figures 7G, S6L , and S6M). Since no information was available in this data set on site of relapse, we interrogated a separate annotated cohort assembled by The International Cancer Genome Consortium (ICGC) that included whole-tissue transcriptome analyses and data on relapse pattern and survival after surgery. In this case, RUNX3 transcript levels did not correlate with either survival or relapse site, an unsurprising result given that PDA are dominated by inflammatory cells with high baseline RUNX3 levels, and whole-tissue preparations from biopsies would inevitably include transcripts from all cell populations. We instead assessed the downstream targets of epithelial RUNX3 expression and found elevated tissue levels of SPP1 and COL6A1 in patients who developed distant as opposed to local disease recurrence after surgery ( Figure 7H) .
As a final measure of potentially actionable information contained in RUNX3 levels, we investigated whether they could help inform the choice and sequencing of different treatment modalities in the post-operative and, by extension, pre-operative settings. We reasoned that patients with lower levels of RUNX3 might respond better to radiotherapy, given the higher risk of local relapse, whereas patients with high RUNX3 might fare better with systemic therapy. As predicted, the use of local radiation favored patients with low RUNX3 (Figure 7I ). Conversely, patients with high RUNX3 benefitted most from systemic treatment, whereas those with low RUNX3 did not (and may even (legend continued on next page) have been harmed given that low RUNX3 should otherwise portend a better prognosis). These analyses support the idea that RUNX3 levels in the primary tumor may help inform the management of pancreas cancer patients.
DISCUSSION
We systematically varied Dpc4/Smad4 gene dosage in Kras G12D/+ ;Trp53 R172H/+ ;p48 Cre/+ (KPC) PDA recapitulating the spectrum of disease presentations encountered in patients and identified the Runx3/RUNX3 transcription factor as the convergence point for several inputs that ultimately govern the balance between cell division and dissemination. RUNX3 slows the proliferation of PDA cells while endowing them with the ability to both migrate to and participate in the construction of the metastatic niche by secreting critical stromal matrix constituents. These findings suggest additional therapeutic targets in pancreas cancer and have the potential to inform clinical decision-making at key junctures in disease management.
Balancing Proliferation and Dissemination in PDA
The cellular demands of proliferation and dissemination appear to compete in pancreas cancers, at least until Dpc4 signaling is completely lost. Our data suggest that partial attenuation of TGF-b signaling shifts the burden of disease toward primary tumor growth by lowering barriers to proliferation at the expense of sacrificing mediators of metastasis. Governing this switch is the transcription factor Runx3, which integrates inputs from Dpc4 and Trp53 ( Figure 6G ) to generate three broad sets of biological behavior. These shifts in pathobiology with mutational state also help explain patterns of spread observed in patients. At one extreme are patients with locally invasive and destructive tumors and minimal discernible dissemination; at the other are patients with a more restricted primary tumor but widespread metastases. Complete loss of Dpc4 in the context of point mutant Trp53 reveals a third state: uninhibited primary tumor growth together with high metastatic potential. It may seem paradoxical that diminution of Dpc4 signaling can impede dissemination, given that loss of expression frequently, though not always (Iacobuzio-Donahue et al., 2009) , occurs in PDA metastases. However, the precise levels of signaling appear to be critically important. Approximately half of conventional PDA lose expression of DPC4/SMAD4 and this is thought to represent a late event . As these data are derived from IHC observations, they are generally bimodal (i.e., all or none) and cannot reliably report heterozygous loss of DPC4. In autopsy series of PDA patients, a range of metastatic disease burdens has been observed, with death not infrequently attributable to local destruction as opposed to disseminated disease (Iacobuzio-Donahue et al., 2009) . Two distinct patterns of metastatic spread emerge: widely metastatic disease characteristic of the majority of cases and an oligometastatic state in a minority. In light of our findings, the most aggressive disease presentation plausibly involves heterozygous mutation of DPC4 relatively early in disease progression, promoting aggressive local growth and invasion; subsequent loss of DPC4 expression from the remaining allele in a subclone would then give rise to a highly metastatic subpopulation. Indeed, in the few KPDC animals that showed metastatic disease, the tumor cells in those metastases had frequently lost Dpc4 expression. In this setting, survival would be threatened by the sequelae of both local and disseminated disease burdens in a highly lethal combination.
Resolving Conflicting Roles of RUNX3 in Tumor Progression RUNX3 has previously been proposed as both promoting and suppressing cancer progression, and sometimes ascribed contradictory roles in the same cancer. Although several studies point toward a tumor suppressive role for RUNX3 (e.g., Bae and Choi, 2004; Lee et al., 2013) , a small number of reports indicate that its oncogenic activity might extend beyond murine lymphomas to include basal cell, skin, head and neck, and ovarian cancers (Chuang and Ito, 2010) . In gastric carcinoma, RUNX3 has been identified as both a TSG (e.g., Li et al., 2002) and an oncogene (e.g., Levanon et al., 2011) . The controversy notwithstanding, these studies may in fact reflect a multifaceted role for RUNX3 signaling, consistent with the dual and contextdependent role of TGF-b signaling as a whole. We propose that RUNX3 indeed functions as both tumor suppressor and promoter, depending not only on the genetic and cellular contexts but also on the specific behavior in question, namely, primary tumor growth or metastatic spread.
EMT and Disease Dissemination: An Imperfect Relationship Both highly metastatic (KPC) and poorly metastatic (KPDC) PDA cells manifested the classic phenotypic and molecular features of EMT in response to TGF-b. Epithelial cells from highly metastatic KPDDC tumors, on the other hand, were resistant to EMT and remained in close contact with each other. Thus, attempting to extrapolate the potential to metastasize in vivo from the ability to morph in vitro seems tenuous at best. Indeed, despite its intuitive appeal as the malignant mimic of the cellular plasticity required during embryogenesis, positing the EMT as an essential feature of the metastatic program remains controversial (Tarin et al., 2005) . The considerable in vitro data in support of the concept are counterbalanced by a lack of in vivo evidence in autochthonous human cancers. Our data suggest that if EMT does occur, it is not the only means by which metastases can develop, at least not in pancreas cancer. RUNX3 may promote distinct, perhaps overlapping, metastatic programs involving the dissemination of both single cells and groups or clusters of cells, a possibility first considered over four decades ago (Fidler, (J) RUNX3 and DPC4 levels coordinately help inform clinical decision making for resectable PDA. These considerations are exploratory and not intended as proscriptive advice. Future prospectively collected information, perhaps augmented with retrospective analyses, will be essential to substantiate, revise, or reject this working framework.
1 An alternative would be a short course of radiotherapy followed by chemotherapy.
See also Figure S6 .
1973) and revisited more recently (Friedl and Alexander, 2011) . As a principal cause of cancer mortality, understanding the basis for and learning how to inhibit metastasis are of more than academic interest. Current efforts to target specific features of EMT as a strategy for disrupting dissemination may be incomplete, and the model systems developed and described here revealing distinct metastatic programs may prove fruitful in future investigations.
Local Growth versus Disseminated Disease: Therapeutic Implications
The unusual ability of PDA to spread has spurred efforts to advance systemic neoadjuvant therapies and address at the outset the almost inevitable and frequently rapid appearance of metastases. This strategy is not without risks: beyond the potential toxicities looms the possibility that a previously contained tumor will breach the immediate confines of resectability. Indeed, a minority of early-stage (I/II) or locally advanced (stage III) tumors are destined to remain local; these patients can often be managed for many months with no overt evidence of dissemination. In such patients, treating with chemotherapy first and delaying surgery may forfeit the rare window to operate. In a large meta-analysis of over 4,000 early-stage pancreas cancer patients who received some form of neoadjuvant therapy, fully 30% became inoperable during the course of treatment (Gillen et al., 2010) . The ideal types, timing, duration, and sequence of adjuvant chemotherapy and radiotherapy are also unclear, with the role of radiation being especially contentious (Katz et al., 2010) . Conflicting results in the setting of complex trial designs have confounded meaningful comparisons and precluded consensus on how best to incorporate distinct modalities into PDA management. Taking the specific case of early-stage disease as an example, distinguishing those patients to treat with neoadjuvant therapy from those to resect immediately remains especially challenging. The studies presented here suggest that RUNX3 may help inform such decisions, particularly when interpreted in the context of DPC4 status ( Figure 7J ). High levels of RUNX3 increase the migratory and metastatic potential of both murine and human PDA cells, which, in the context of intact DPC4, defines the most likely cause of death. These patients would likely benefit most from initial systemic therapy followed by resection given the comparatively lower risk for local growth. Patients with resectable disease and low RUNX3 levels benefit less from systemic treatment up front and should instead be resected (or treated with a short course of radiation prior to resection, if needed). Patients with high RUNX3 and complete loss of DPC4 pose the greatest challenge: if neoadjuvant therapy is attempted at all, it may make sense to invert the normal sequence and give a short course of chemoradiation to achieve some local control prior to systemic cytotoxics; however, the primary tumor must be followed closely so as not to lose the opportunity for a definitive resection. Alternatively, combining systemic therapy with cell-cycle inhibitors may allow treatment of occult disseminated disease while minimizing the risks of local tumor growth. These admittedly speculative hypotheses nevertheless suggest a framework for future studies that will ultimately provide the measure of their merit.
EXPERIMENTAL PROCEDURES
Additional experimental details can be found in Supplemental Experimental Procedures. , and p48
Mouse Strains
Cre/+ mice strains described earlier (Hingorani et al., 2003 (Hingorani et al., , 2005 Izeradjene et al., 2007) 
Histology and Immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin and embedded in paraffin, and 5-mm sections were prepared. Routine H&E and immunohistochemistry (IHC) were performed as previously described (Hingorani et. al., 2003) and IHC scoring was done blinded. Biotinylated secondary antibody and the Elite vectastain kit (Vector Laboratories) were used for signal detection and DAB was used as a chromogen substrate. 
Assessment of Primary and Metastatic Disease Burden
Complete necropsies were performed on all study animals. Gross pathology and histopathology of all internal organs were analyzed for macroscopic and microscopic disease, respectively. Primary (1 ) histology was defined as representing R50% assessed tissue; secondary (2 ) histology involved >25% but <50%.
Statistical Analyses
Unless otherwise indicated, the significance of data was determined by the Student's t test (two-tailed) for all in vitro studies. A value of p < 0.05 was deemed significant. Fisher's exact t test was performed for comparison of metastatic disease burdens in KPC versus KPDC cohorts. All statistical analyses were performed using GraphPad Prism 6.0 software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, six figures, and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2015.04.048.
